Brain
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A071102
Primary Category:
Treatment Protocols
A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant
Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Alliance A071102 is permanently closed to new patient registration (Step 1) effective October 15, 2018.
NCT#02152982
(Click for More Info)
ALLIANCE A071401
Primary Category:
Treatment Protocols
Status:
Temporarily Closed
Phase II Trial of SMO / AKT / NF2 Inhibitors in Progressive Meningiomas with SMO / AKT / NF2 Mutations
The A071401 NF2 Grade I and NF2 Grade II/III cohorts have met their accrual goals. Therefore, EFFECTIVE 07/19/17, no new patients may register (Step 1) to the NF2 Grade I or Grade II/III cohorts.
NCT#02523014
(Click for More Info)
Effective immediately on 02/07/18, pre-registration (Step 0) and registration (Step 1) to A071401 have been temporarily suspended. The manufacturer of the investigational agent vismodegib has discontinued provision to new patients on A071401. Therefore, effectively immediately, the SMO/PTCH1 Grade I and SMO/PTCH1 Grade II/III cohorts on A071401 are closed to new patient registration (Step 1).
ALLIANCE A071601
Primary Category:
Treatment Protocols
Status:
Open, Temporarily Closed
Coverage Analysis WorksheetPhase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
NCT#03224767
(Click for More Info)
ALLIANCE A071701
Primary Category:
Treatment Protocols
Disease Category:
Brain, Brain Metastatic, Molecular Profiling
Genomically-Guided Treatment Trial in Brain Metastases
(Click for More Info)
ALLIANCE A071702
Primary Category:
Treatment Protocols
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma
(Click for More Info)
NCT#04145115
ALLIANCE A071801
Primary Category:
Radiation Oncology
Disease Category:
Brain, Brain Metastatic
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
NCT#04114981
(Click for More Info)
ALLIANCE A221208
Primary Category:
Cancer Control and Prevention Protocols, Radiation Oncology
Disease Category:
Brain Metastatic
Randomized Phase II Study: Corticosteroids and Bevacizumab vs. Corticosteroids and Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases
A221208 is closed to accrual effective December 15, 2018.
Eligible for screening study DCP 001
NCT#02490878
(Click for More Info)
ALLIANCE CCTG CE.7
Primary Category:
Radiation Oncology
Disease Category:
Brain, Brain Metastatic
A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases
For CCTG CE.7, please credit ALLIANCE all accruals.
NCT#03550391
(Click for More Info)
CCTG CE.7 has reopened with Amendment 1 to resume patient accrual at your center, your site will be required to provide confirmation of HA-WBRT credentialing and approval by IROC.
ALLIANCE N0577
Primary Category:
Radiation Oncology, Treatment Protocols
Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
Eligible for screening study DCP 001
NCT#00887146
(Click for More Info)
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG BN003
Primary Category:
Radiation Oncology, Treatment Protocols
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Eligible for screening study DCP 001
NCT#03180268
(Click for More Info)
NRG BN007
Primary Category:
Radiation Oncology, Treatment Protocols
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
(Click for More Info)
NCT#04396860
NRG CC003
Primary Category:
Radiation Oncology
Disease Category:
Brain, Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage
Randomized Phase II/III Trial of Prophylatic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
NCT#02635009
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
Breast
AFT-25 COMET
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Breast, Breast DCIS
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
NCT#02926911
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Sites must submit to MCC a protocol specific Training Log and an AFT Delegation of Authority Log before any patient registrations may take place.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A011106
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Eligible for screening study DCP 001
NCT#01953588
(Click for More Info)
Effective today, July 15th, 2019, study A011106 is permanently closed to new patient registration.
ALLIANCE A011202
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
Effective 09/01/20, OPEN Step 2 (Confirmation of Evaluability) is temporarily unavailable for new registration.
NCT#01901094
(Click for More Info)
ALLIANCE A011203
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
NCT#02311933
(Click for More Info)
A011203 is permanently closed to accrual effective May 19, 2017.
ALLIANCE A011401
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Eligible for screening study DCP 001
NCT#02750826
(Click for More Info)
The A011401 Health Behaviors and Patient Reported Outcomes substudy HO1 will soon meet its study accrual goal. Therefore, EFFECTIVE July 06, 2017 at 4:30 pm ET, A011401 substudy HO1 will permanently close to new patient accrual.
ALLIANCE A011502
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
A011502 is approaching accrual goal Therefore, permanent closure is scheduled for December 4, 2020.
Patients previously enrolled in A011502 patients are eligible for enrollment in companion study A211601 and may be consented with A211601 Retrospective Consent.
Patients enrolling in A011502 patients must be enrolled in companion study A211601 and may be consented with A211601 Consent.
Eligible for screening study DCP 001
NCT#02927249
(Click for More Info)
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A171601
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
NCT#03633331
(Click for More Info)
Eligible for screening study DCP 001
Effective Tuesday, March 3rd, 2020, at 4:30 PM ET, study A171601 is permanently closed to new patient registration.
ALLIANCE A211601
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Adjuvant Breast, Breast
Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502
NCT#03609021
(Click for More Info)
Patients previously enrolled in A011502 are eligible to be enrolled in this protocol using the A211601 Retrospective Consent.
Eligible for screening study DCP 001
ALLIANCE A221505
Primary Category:
Radiation Oncology, Surgical Protocols
Disease Category:
Adjuvant Breast, Breast
Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
NCT#03414970
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A221701
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Gastrointestinal, Genitourinary, Neuroendocrine, Pancreatic, Renal
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention versus Early Treatment Approaches
NCT#03839940
(Click for More Info)
Eligible for screening study DCP 001
A221701 is closed to new patient accrual, effective November 1, 2020.
ALLIANCE A221702
Primary Category:
Surgical Protocols
Disease Category:
Adjuvant Breast, Breast
ARM: Axillary Reverse Mapping – A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping
Eligible for screening study DCP 001
(Click for More Info)
ALLIANCE A231701CD
Primary Category:
Cancer Care Delivery, Surgical Protocols
Disease Category:
Breast, Cancer Care Delivery
Increasing Socioeconomically Disadvantaged Patients’ Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention
NCT#03766009
A231701CD is reopened to new patient registration and site registration effective, Wednesday, June 17, 2020.
(Click for More Info)
Limited institution study – Only open to: Billings Clinic
ECOG-ACRIN E2108
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic, Breast Neoadjuvant
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
E2108 is closed to accrual effective July 23, 2015 at 5:00 p.m. EDT.
NCT#01242800
(Click for More Info)
ECOG-ACRIN E5103
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
E5103 Step 3 registration, registration to the EL112LAB substudy, will close to accrual on July 29, 2016.
NCT#00433511
(Click for More Info)
ECOG-ACRIN EA1131
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#02445391
(Click for More Info)
ECOG-ACRIN EA1151
Primary Category:
Cancer Control and Prevention Protocols
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Limited institution study: open only to Saint Alphonsus Health System.
(Click for More Info)
NCT#03233191
ECOG-ACRIN EA1181
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
(Click for More Info)
NCT#04266249
ECOG-ACRIN EA1183
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
(Click for More Info)
NCT#04316117
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
ECOG-ACRIN PACCT-1
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
Ancillary study EL112LAB for the PACCT1 Trial has reached its accrual goal. Therefore, PACCT1 Step 3 registration (EL112LAB) will be closed to accrual effective Friday, July 3, 2015 at 5:00 pm EST. (E5103 accrual remains open for EL112LAB.)
NCT#00310180
(Click for More Info)
NRG B-51
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#01872975
(Click for More Info)
NSABP B-51 is projected to meet accrual goal during the 1st Quarter of 2021. Closure date pending.
The accrual goal for the Behaviorial and Health Outcomes (BAHO) Quality of Life component in the B-51 trial has been met. Therefore, effective August 6th, 2018, accrual will be closed to the QoL component. The B-51 trial remains open to accrual.
NRG B-52
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
B-52 is closed to accrual effective February 29, 2016, 8 pm EST.
NCT#02003209
(Click for More Info)
NRG B-55
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#02032823
(Click for More Info)
B-55 is closed to accrual effective April 29, 2019.
Closure of Part 1 and Part 2 Screening will occur on April 1, 2019 at 5:00 PM Eastern Time. Accrual to the NSABP B-55/BIG 6-13 trial will close on April 29, 2019 at 5:00 PM Eastern Time. Patients, who are in screening, must be randomized to the study by 5:00 PM on April 29, 2019.
Protocol
NRG BR002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Temporarily Closed
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Effective, Friday, September 13th, 2019, study NRG BR002 is temporarily closed to accrual at 3 p.m. MST.
NCT#02364557
(Click for More Info)
NRG BR003
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Eligible for screening study DCP 001
NCT#02488967
(Click for More Info)
NRG BR004
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
NCT#03199885
(Click for More Info)
NRG BR005
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Status:
Temporarily Closed
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery
NCT#03188393
Effective today, July 2, 2019, study NRG BR005 is temporarily closed to accrual.
(Click for More Info)
NRG CC004
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Gynecologic
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
Eligible for screening study DCP 001
NCT#03180294
(Click for More Info)
NRG CC004 is permanently closed to accrual, due to drug expiration dates. All patients registered to Step 1 registration by 5pm ET, Friday, April 24, 2020 will be permitted to proceed to the randomization step (Step 2).
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
NRG CCTG MA.39
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
For CCTG MA.39, please credit NRG all accruals.
NCT#03550391
(Click for More Info)
SWOG S1007
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
S1007 will be permanently closed to accrual for Step 1 registration effective October 1, 2015 at 11:59 p.m. PST. The study will be permanently closed to accrual for Step 2 registration effective October 15, 2015 at 11:59 p.m. PST. Patients who will be registered to Step 1 and Step 2 at the same time (patients whose Recurrence Score is already known) must be registered prior to closure of Step 1
registration on October 1, 2015.
NCT#01272037
(Click for More Info)
SWOG S1207
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy
NCT#01674140
(Click for More Info)
S1207 is closed to accrual effective May , 2019.
Eligible for screening study DCP 001
SWOG S1416
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
NCT#02595905
(Click for More Info)
Effective, today, June 15th, 2019, SWOG S1416, is permanently closed to accrual.
SWOG S1418
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#02954874
(Click for More Info)
Site Delegation of Tasks Log required prior to registration of any patients.
Effective June 23, 2020, the BAHO substudy for SWOG study S1418/BR006, is permanently closed to accrual.
SWOG S1501
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Eligible for screening study DCP 001
NCT#03418961
(Click for More Info)
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
SWOG S1703
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NCT#03723928
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1706
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
NCT#03598257
(Click for More Info)
Cancer Care Delivery
ALLIANCE A231701CD
Primary Category:
Cancer Care Delivery, Surgical Protocols
Disease Category:
Breast, Cancer Care Delivery
Increasing Socioeconomically Disadvantaged Patients’ Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention
NCT#03766009
A231701CD is reopened to new patient registration and site registration effective, Wednesday, June 17, 2020.
(Click for More Info)
Limited institution study – Only open to: Billings Clinic
ECOG-ACRIN EAQ162CD
Primary Category:
Cancer Care Delivery, Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery, Colon, Gastrointestinal, Rectal
Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
NCT#03516942
(Click for More Info)
Eligible for screening study DCP 001
EAQ162CD closed to accrual Monday, July 6, 2020.
ECOG-ACRIN EAQ171CD
Primary Category:
Cancer Care Delivery
Disease Category:
Cancer Care Delivery
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: “Smoke Free Support Study 2.0”
NCT#03808818
(Click for More Info)
Contact Amanda Dinsdale at 406-969-6063 or adinsdale@mtcancer.org if your site is interested in participating in this study.
SWOG S1415CD
Primary Category:
Cancer Care Delivery, Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery
A Pragmatic Trial Evaluating a Colony Stimulating Factor Intervention in Standing Orders and the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia
Limited site participation. Open only to Billings Clinic, Bozeman Health, and Saint Alphonsus
Effective December 2nd, 2019, study S1415CD will be permanently closed to low or high risk accruals. Intermediate risk accrual remains open for randomized sites.
Closed to accrual effective April 15, 2020. Accrual goals met.
NCT#02728596
(Click for More Info)
Eligible for screening study DCP 001
WAKE WF-1803CD
Primary Category:
Cancer Care Delivery
Disease Category:
Cancer Care Delivery
Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices
NCT#03746314
(Click for More Info)
Contact Amanda Dinsdale at 406-969-6063 or adinsdale@mtcancer.org if your site is interested in participating in this study.
Gastrointestinal
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A021502
Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Eligible for screening study DCP 001
NCT#02912559
(Click for More Info)
Site Delegation of Tasks Log required prior to registration of any patients.
ALLIANCE A021602
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A021703
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Eligible for screening study DCP 001
NCT#04094688
(Click for More Info)
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A221701
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Gastrointestinal, Genitourinary, Neuroendocrine, Pancreatic, Renal
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention versus Early Treatment Approaches
NCT#03839940
(Click for More Info)
Eligible for screening study DCP 001
A221701 is closed to new patient accrual, effective November 1, 2020.
ALLIANCE A221805
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Colon, Gastrointestinal, Rectal
Status:
Temporarily Closed
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Temporarily closed to new patient accrual effective 11/19/2020
Eligible for screening study DCP 001
(Click for More Info)
NCT#04137107
ALLIANCE C80702
Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
CALGB 80702 is permanently closed to new patient accrual effective, November 20. 2015 at 4:30 PM ET.
NCT#01150045
(Click for More Info)
ALLIANCE N1048
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Rectal
A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)
Eligible for screening study DCP 001
NCT#01515787
(Click for More Info)
N1048 is permanently closed to new patient accrual effective Friday, December 28, 2018 at 4:30 PM ET.
ECOG-ACRIN EA2142
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Neuroendocrine
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
(Click for More Info)
NCT#02595424
ECOG-ACRIN EA2165
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Anal, Gastrointestinal
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
NCT#03233711
(Click for More Info)
ECOG-ACRIN EA2182
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Anal, Gastrointestinal
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
NCT#04166318
(Click for More Info)
ECOG-ACRIN EA2183
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Esophageal, Esophageal Metastatic, Gastrointestinal, Stomach, Stomach Metastatic
A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
NCT#04248452
(Click for More Info)
Eligible for screening study DCP 001
ECOG-ACRIN EA2186
Primary Category:
Surgical Protocols, Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic Metastatic
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
(Click for More Info)
NCT#04233866
ECOG-ACRIN EA2187
Primary Category:
Treatment Protocols
Disease Category:
Cholangiocarcinoma, Gastrointestinal
A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
(Click for More Info)
NCT#04175912
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAQ162CD
Primary Category:
Cancer Care Delivery, Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery, Colon, Gastrointestinal, Rectal
Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
NCT#03516942
(Click for More Info)
Eligible for screening study DCP 001
EAQ162CD closed to accrual Monday, July 6, 2020.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG GI002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Rectal
Status:
Temporarily Closed
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
NCT#02921256
(Click for More Info)
As of February 12, 2018 Arm 2 is permanently closed having met its enrollment goal.
As of Tuesday, May 14th, 2019 at 9:00 am EST, NRG-GI002 (Arm 1 and 3) has met its accrual goal and is temporarily suspended.
NRG GI004
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Status:
Temporarily Closed
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Eligible for screening study DCP 001
NRG GI004 is temporarily closed to accrual effective June 4, 2020 5pm EDT ,
NCT#02997228
(Click for More Info)
Site Delegation of Tasks Log required prior to registration of any patients.
NRG GI005
Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
NCT#04068103
(Click for More Info)
NRG R0848
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
NCT#01013649
(Click for More Info)
Eligible for screening study DCP 001
R0848 will close to accrual at 5 PM ET Friday, June 1, 2018, because it has reached its accrual target. Step 2 randomization will remain open. All patients registered to Step 1 by Friday, June 1, 2018 will proceed to the randomization step (Step 2). If patients are unable to be randomized, Step 2 will still be completed with the reason for no randomization being provided.
NRG R1010
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Esophageal, Gastrointestinal
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
R1010 will close to STEP 1 registration at 5 PM EST on Tuesday, November 10, 2015, because the study has reached its accrual target. STEP 2 registration will remain open and all eligible patients determined to be HER2 positive will be permitted to be randomized for treatment on this trial.
NCT#01196390
(Click for More Info)
SWOG S1513
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic, Pancreatic Metastatic
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
NCT#02890355
(Click for More Info)
S1513 is permanently closed to accrual effective immediately. 12/13/17. At a planned interim analysis, our Data and Safety Monitoring Committee recommended that S1513 be closed permanently based on the results. These results will be shared, and further instructions given in a forthcoming letter to patients and investigators. Patients currently receiving ABT-888 (Veliparib) must discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.
SWOG S1613
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
NCT#03365882
(Click for More Info)
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
SWOG S1815
Primary Category:
Treatment Protocols
Disease Category:
Cholangiocarcinoma, Gallbladder, Gastrointestinal
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Eligible for screening study DCP 001
NCT#03768414
(Click for More Info)
S1815 is reactivated to accrual effective, June 5, 2020.
SWOG S1820
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Colon, Gastrointestinal, Rectal
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
NCT#04205955
(Click for More Info)
SWOG S1922
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Small Bowel
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
NCT#04205968
(Click for More Info)
Genitourinary
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A031102
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Eligible for screening study DCP 001
NCT#02375204
(Click for More Info)
ALLIANCE A031201
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Phase III Trial of Enzalutamide (NSC #766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
A031201 is permanently closed to new patient accrual, effective August 31, 2016.
NCT#01949337
(Click for More Info)
ALLIANCE A031203
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Effective Monday, April 6th, 2015 at 4:30 PM (ET), Alliance A031203 permanently closed to new patient accrual.
NCT#01835158
(Click for More Info)
ALLIANCE A031501
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
NCT#03244384
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A031701
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
NCT#03609216
(Click for More Info)
ALLIANCE A031702
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary, Prostate, Renal
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
(Click for More Info)
NCT#03866382
ALLIANCE A031704
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
(Click for More Info)
Eligible for screening study DCP 001
NCT#03793166
ALLIANCE A031801
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)
NCT#04071223
(Click for More Info)
ALLIANCE A031803
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
NCT#04164082
(Click for More Info)
07/19/17, no new patients may register (Step 1) to the NF2 Grade I or Grade II/III cohorts.
NCT#02523014
(Click for More Info)
Effective 09/30/20, new patient registration (Step 1) of A031803 is reopened to accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A221701
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Gastrointestinal, Genitourinary, Neuroendocrine, Pancreatic, Renal
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention versus Early Treatment Approaches
NCT#03839940
(Click for More Info)
Eligible for screening study DCP 001
A221701 is closed to new patient accrual, effective November 1, 2020.
ALLIANCE C90203
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
CALGB 90203 is permanently closed to new patient accrual effective Friday, October 2, 2015 at 4:30 PM EST.
NCT#00430183
(Click for More Info)
ECOG-ACRIN EA8143
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Eligible for screening study DCP 001
NCT#03055013
(Click for More Info)
Quality of Life (QOL) component reached its accrual goal. Therefore, QOL is closed to new patient accrual effective June 19, 2020.
Site Delegation of Tasks Log required prior to registration of any patients.
ECOG-ACRIN EA8153
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
NCT#03419234
(Click for More Info)
ECOG-ACRIN EA8171
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
NCT#03697148
(Click for More Info)
ECOG-ACRIN EA8185
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive BladdeR CancEr (INSPIRE)
(Click for More Info)
NCT#04216290
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG GU002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
NCT#03070886
(Click for More Info)
NRG GU003
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Eligible for screening study DCP 001
NCT#03274687
(Click for More Info)
GU003 is closed to accrual effective July 9, 2018, because it has reached its accrual target. All patients registered to Step 1 registration by Monday, July 9, 2018 will be permitted to proceed to the randomization step (Step 2).
NRG GU005
Primary Category:
Radiation Oncology
Disease Category:
Genitourinary, Prostate
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Eligible for screening study DCP 001
NCT#03367702
(Click for More Info)
RT Credentialing Required
Because the AJCC staging version 8 was not ready for the study activation, AJCC staging version 7 must be used.
NRG GU006
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Recurrent
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
NCT#03371719
NRG-GU006 permanently closed to accrual, effective May 19, 2020, because it has reached its accrual target.
(Click for More Info)
NRG GU007
Primary Category:
Radiation Oncology
Disease Category:
Genitourinary, Prostate
Status:
Open, Temporarily Closed
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
NCT#04037254
GU007 is temporarily closed effective 09/16/20, for a protocol-specified toxicity analysis.
(Click for More Info)
NRG GU008
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
(Click for More Info)
NCT#04134260
NRG R0521
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
NCT#00288080
(Click for More Info)
R0521 is closed to accrual effective August 21. 2009.
NRG R0534
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Recurrent
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
NCT#00567580
(Click for More Info)
R0534 closed to accrual at 5 PM EST Monday, March 30, 2015, because it reached its accrual target.
NRG R0815
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
R0815 will close to accrual at 5 PM EST on Monday, March 7, 2016, because the study has reached its accrual target.
NCT#00936390
(Click for More Info)
Protocol
NRG R0924
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Effective today, June 24th, 2019, study RTOG 0924 has reached its accrual goal and is now closed.
(QOL Sub-study is closed as its accrual goal has been met.)
Eligible for screening study DCP 001
NCT#01368588
(Click for More Info)
SWOG S0931
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
S0931 has met its accrual goal and will permanently close to accrual effective September 15, 2016 at 11:59 p.m. Pacific Time.
NCT#01120249
(Click for More Info)
SWOG S1216
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
NCT#01809691
(Click for More Info)
S1216 has met its accrual goal and will permanently close to accrual effective July 15, 2017 at 11:59 p.m. Pacific.
SWOG S1314
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
NCT#02177695
(Click for More Info)
S1314 has met its accrual goal and will permanently close to accrual effective December 1, 2017 at 11:59 p.m. Pacific.
SWOG S1500
Primary Category:
Treatment Protocols
Disease Category:
Renal, Renal Metastatic
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
NCT#02761057
(Click for More Info)
Effective December 15th, 2019, study S1500 will be permanently closed to accrual.
SWOG S1602
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer
NCT#03091660
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
SWOG S1802
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
NCT#03678025
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1806
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
(Click for More Info)
NCT#03775265
Gynecologic
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
GOG Foundation GOG-3015 / Y039523
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian, Ovarian Metastatic
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT#03038100
(Click for More Info)
Limited institution study: Open ONLY to Billings Clinic, Bozeman Deaconess Cancer Center & Community Medical Center – Missoula
GOG Foundation GOG-3024/GCT1015-05
Primary Category:
Treatment Protocols
Disease Category:
Cervical, Cervical Metastatic, Gynecologic
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
NCT#03786081
(Click for More Info)
NRG CC004
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Gynecologic
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
Eligible for screening study DCP 001
NCT#03180294
(Click for More Info)
NRG CC004 is permanently closed to accrual, due to drug expiration dates. All patients registered to Step 1 registration by 5pm ET, Friday, April 24, 2020 will be permitted to proceed to the randomization step (Step 2).
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
NRG CC008
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Ovarian
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]
Eligible for screening study DCP 001
(Click for More Info)
NCT#04251052
NRG G0212
Primary Category:
Treatment Protocols
Disease Category:
GYN Other, Gynecologic, Ovarian
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND # 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
NCT#00108745
(Click for More Info)
NRG G0263
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Eligible for screening study DCP 001
NCT#01101451
(Click for More Info)
NRG G0274
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Eligible for screening study DCP 001
NCT#01414608
(Click for More Info)
Please be aware that as of the 1st June 2017, sites are no longer permitted to screen for or provide informed consent forms for potential OUTBACK/GOG274/RTOG1174 patients as the protocol has reached its accrual goal.
NRG G0286B
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
NCT#02065687
(Click for More Info)
GOG-0286B will be permanently closed to accrual effective today, February 1, 2018 due to futility.
NRG GY004
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum sensitive ovarian, fallopian tube, or primary peritoneal cancer
NCT#02446600
(Click for More Info)
Closed to accrual effective November 10, 2017. Accrual goal met.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
NRG GY005
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
NCT#02502266
(Click for More Info)
GY005 closed to accrual effective 10/02/20.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
NRG GY006
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
NCT#02466971
(Click for More Info)
NRG GY009
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian, Ovarian Metastatic
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
NCT#02839707
(Click for More Info)
NRG-GY009 is reactivated to Phase III portion effective August 25, 2020.
NRG GY011
Primary Category:
Surgical Protocols
Disease Category:
Endometrial, Gynecologic
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
NCT#03018249
(Click for More Info)
NRG-GY011 has met its accrual goal and closed to patient entry effective February 9, 2018.
NRG GY012
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
Status:
Temporarily Closed
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
NCT#03660826
(Click for More Info)
Effective today, June 17th, 2019, study NRG GY012 has met its accrual goal and is temporarily closed.
NRG GY014
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Gynecologic, Ovarian
Status:
Temporarily Closed
A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
(Click for More Info)
NCT#03348631
NRG GY016
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
Status:
Temporarily Closed
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
NCT#03602586
(Click for More Info)
Effective immediately on 04/10/19, NRG-GY016 has been temporarily closed to accrual because the study has reached its maximum accrual number of 14 patients for the first stage of the trial. Accrual will be stopped until data is matured and the analysis on the first stage is complete.
NRG GY018
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Gynecologic
Status:
Temporarily Closed
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer
Eligible for screening study DCP 001
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
NRG Oncology GY018 is temporarily being suspended to accrual in response to the COVID-19 pandemic while we consider options to responsibly continue the trial in the context of the current placebo design. Patients who have already consented and/or entered Step 1 registration will be allowed to proceed. Step 1 registration must be completed for all consented patients by 12 Noon ET, Monday, April 6, 2020.
(Click for More Info)
NCT#03914612
NRG GY019
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian, Ovarian Metastatic
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Eligible for screening study DCP 001
NRG GY020
Primary Category:
Cancer Care Delivery, Radiation Oncology
Disease Category:
Endometrial, Gynecologic
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Eligible for screening study DCP 001
(Click for More Info)
NCT#04214067
NRG R0724
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Eligible for screening study DCP 001
NCT#00980954
(Click for More Info)
NRG R1203
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Endometrial, Gynecologic
A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
NRG 1203 closed to accrual at 5 PM EST Thursday, August 27, 2015 because it had reached its accrual target.
NCT#01672892
(Click for More Info)
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
Head and Neck
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A091404
Primary Category:
Treatment Protocols
Disease Category:
Head and Neck
A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers
NCT#02749903
(Click for More Info)
Effective August 31, 2018, Alliance A091404 is closed to accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ECOG-ACRIN E1305
Primary Category:
Treatment Protocols
Disease Category:
Head and Neck, Head and Neck Metastatic
A Phase III Randomized Trial of Chemotherapy with or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
NCT#00588770
(Click for More Info)
E1305 is permanently closed to new patient accrual effective February 11, 2015.
ECOG-ACRIN EA3132
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT#02734537
(Click for More Info)
ECOG-ACRIN EA3161
Primary Category:
Treatment Protocols
Disease Category:
Head and Neck
Nivolumab Versus Observation in Treating Patients With Locally Advanced, Intermediate Risk HPV-Positive Oropharyngeal Cancer
NCT#03811015
(Click for More Info)
ECOG-ACRIN EA3163
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Head and Neck
Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
NCT#03493425
(Click for More Info)
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG HN002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
NCT#02254278
(Click for More Info)
Closed effective 02/07/17. Accrual goal met.
NRG HN004
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
NCT#03258554
(Click for More Info)
Site Delegation of Tasks Log required prior to registration of any patients.
NRG HN005
Primary Category:
Radiation Oncology
Disease Category:
Head and Neck
Coverage Analysis WorksheetA Randomized Phase II/II Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Open to Phase II enrollment
(Click for More Info)
NRG HN007
Primary Category:
Treatment Protocols
Disease Category:
Head and Neck, Head and Neck Metastatic
An Open-Label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Eligible for screening study DCP 001
(Click for More Info)
NCT#04458909
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
Leukemia
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
ALLIANCE A041202
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study Of Bendamustine PLUS Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients (≥ 65 Years Of Age) With Chronic Lymphocytic Leukemia (CLL)
A041202 is permanently closed to accrual May 16, 2016 at 4:30 pm ET.
NCT#01886872
(Click for More Info)
ALLIANCE A041501
Primary Category:
Treatment Protocols
Disease Category:
Acute Lymphocytic Leukemia, Leukemia
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
NCT#03150693
(Click for More Info)
Eligible for screening study DCP 001
Confirmation of Tolerability Phase and slot reservation completed and study currently open to Phase III enrollment as of 06/12/2018. See Section 4.4 for registration and randomization instructions.
ALLIANCE A041701
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
NCT#03701308
(Click for More Info)
ALLIANCE A041702
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
NCT#03737981
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A231602CD
Primary Category:
Cancer Care Delivery
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia, Multiple Myeloma
Status:
Open, Temporarily Closed
Assessing Financial Difficulty in Patients with Blood Cancers
NCT#03870633
(Click for More Info)
Eligible for screening study DCP 001
A231602CD has reached accrual goal. Therefore, effective June 9, 2020, it is temporarily closed to accrual. Update to increase is under consideration with trial closed until determination is made.
Limited site participation. Open only to Benefis Sletten Cancer Institute, Billings Clinic, Community Hospital of Anaconda, Community Medical Center, and Saint Alphonsus Regional Medical Center
ECOG-ACRIN E1910
Primary Category:
Treatment Protocols
Disease Category:
Acute Lymphocytic Leukemia, Leukemia
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Eligible for screening study DCP 001
NCT#02003222
(Click for More Info)
Due to the completion of accrual, E1910 will be closed to accrual effective October 15, 2019.
ECOG-ACRIN E1912
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
E1912 closed to accrual June 9, 2016 at 5:00 pm ET due to reaching its accrual goal.
NCT#02048813
(Click for More Info)
ECOG-ACRIN EA9161
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
NCT#03701282
(Click for More Info)
Eligible for screening study DCP 001
EQ9161 Quality of Life (QOL) component has reach accrual goal. Therefore, EFFECTIVE August 5, 2020, the QOL component is closed to new accrual.
ECOG-ACRIN EA9171
Primary Category:
Treatment Protocols
Disease Category:
Chronic Myeloid Leukemia, Leukemia
BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD
NCT#03516279
(Click for More Info)
ECOG-ACRIN NHLBI-MDS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Leukemia, Myelodysplastic Syndrome
The National Myelodysplastic Syndromes (MDS) Study
NCT#02775383
(Click for More Info)
Eligible for screening study DCP 001
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
Suspension to enrollment of new participants and follow-up research sample collection and shipment is lifted effective May 18, 2020, for NHLBI-MDS. Refer to memo dated March 27, 2020, on conducting remote follow-up data for enrolled participants.
SWOG S1203
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
S1203 is fast-approaching its accrual goal and will permanently close to accrual effective November 4, 2015 at 11:59 pm Pacific Time.
NCT#01802333
(Click for More Info)
SWOG S1612
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome
A Randomized Phase II/III Trial of “Novel Therapeutics” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older
NCT#03092674
(Click for More Info)
Effective 09/01/20, S1612 is permanently closed to accrual.
Effective immediately,10/25/18, and until further notice, patients will no longer receive nivolumab as part of this study. Additional details are provided in the Investigator Letter and Patient Information Letter.
SWOG S1712
Primary Category:
Treatment Protocols
Disease Category:
Chronic Myeloid Leukemia, Leukemia
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
NCT#03654768
(Click for More Info)
Lung
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A081105
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
A081105 is reactivated effective July 15, 2020.
NCT#02193282
(Click for More Info)
ALLIANCE A081801
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
(See required screening study ALLIANCE A151216)
(Click for More Info)
NCT#04267848
ALLIANCE A151216
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105, E4512, and EA5142.
Eligible for screening study DCP 001
Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.
NCT#02194738
(Click for More Info)
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A221504
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)
NCT#03087708
(Click for More Info)
Eligible for screening study DCP 001
A221504 is unlikely to meet accrual goal. Therefore, it is permanently closed to accrual effective 06/30/20.
ALLIANCE C140503
Primary Category:
Surgical Protocols
Disease Category:
Lung, Lung - Non-Small Cell
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm)
Peripheral Non-Small Cell Lung Cancer
(See Section 9.0 for required surgical credentialing.)
NCT#00499330
(Click for More Info)
C140503 is permanently closed to accrual effective March 13, 2017 at 4:30 pm EDT.
ALLIANCE C30610
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Limited Stage
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Eligible for screening study DCP 001
NCT#00632853
(Click for More Info)
Effective December 1st, 2019, study CALGB 30610 is permanently closed to new patient accrual.
ECOG-ACRIN E4512
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02201992
(Click for More Info)
ECOG-ACRIN E5508
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
E5508 is approaching its Step 1 accrual goal. Therefore, this study will close Step 1 accrual effective May 8, 2015 at 5:00 p.m. EST for registrations. Patients registered to Step 1 by this time may still register to Step 2 as outlined in the protocol.
NCT#01107626
(Click for More Info)
ECOG-ACRIN EA5142
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02595944
(Click for More Info)
Effective today, October 1st, 2019, study EA5142 has met accrual goals and is permanently closed to accrual.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
ECOG-ACRIN EA5161
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
NCT#03382561
(Click for More Info)
EA5161 is closed to accrual effective December 7, 2018 at 5:00 PM ET.
ECOG-ACRIN EA5162
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Temporarily Closed
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
NCT#03191149
(Click for More Info)
Effective, July 2, 2019, study EA5162 is temporarily closed to accrual.
ECOG-ACRIN EA5163
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
NCT#03793179
Eligible for screening study DCP 001
(Click for More Info)
ECOG-ACRIN EA5181
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Eligible for screening study DCP 001
(Click for More Info)
NCT#04092283
ECOG-ACRIN EA5191
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell Metastatic
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
(Click for More Info)
NCT#04310007
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG CC003
Primary Category:
Radiation Oncology
Disease Category:
Brain, Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage
Randomized Phase II/III Trial of Prophylatic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
NCT#02635009
(Click for More Info)
Eligible for screening study DCP 001
NRG LU001
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC
LU001 is closed effective December 15, 2016 because it has reached its accrual target.
NCT#02186847
(Click for More Info)
NRG LU002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
NCT#03137771
(Click for More Info)
NRG LU003
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol
(Click for More Info)
NCT#03737994
Treatment consent forms for individual agents for this study are available upon request when a patient at your site is assigned to a study agent. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consents & for any questions.
NRG LU004
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined with MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
NCT#03801902
(Click for More Info)
LU004 is reopened to accrual effective July 16, 2020.
NRG LU005
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Limited Stage
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Site staff must complete Rave ePro online training prior to the first patient enrollment.
NCT#03811002
(Click for More Info)
NRG LU007
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
(Click for More Info)
NCT#04402788
SWOG LUNGMAP
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
NCT#03851445
(Click for More Info)
Eligible for screening study DCP 001
Effective, June 30th, 2019, the sub-study S1400GEN is closed to accrual.
SWOG S1400
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Eligible for screening study DCP 001
NCT#02154490
(Click for More Info)
Closure to accrual for S1400 is effective January 28, 2019.
SWOG S1400A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Permanent Closure of S1400A, Arm 2-Docetaxel due to FDA approval of nivolumab. Permanent closure of sub-study due to a revised trial design.
NCT#02154490
(Click for More Info)
SWOG S1400B
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
S1400B is closed to accrual effective December 12, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400C
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Permanent closure of Arm 2 ONLY due to a revised trial design.
S1400C will be permanently closed to accrual, effective September 1, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400D
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Effective 11:59 p.m. Pacific Time on October 31, 2016, the following sub-study will be permanently closed to accrual, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400E
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-MET Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
(See required screening study SWOG S1400)
NCT#02154490
(Click for More Info)
SWOG S1400F
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTIPD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)
See Screening Protocol LUNGMAP
NCT#03373760
(Click for More Info)
Effective November 6th, 2019 at 2:00 pm Pacific Time, Cohort 1, the acquired resistance cohort of substudy S1400F will permanently close to accrual. Please note that Cohort 2, the primary resistance cohort, has been reactivated and is open to accrual.
S1400F Cohort 2, the primary resistance cohort, will be permanently closed to accrual effective March 24, 2020 at 12:00 p.m. Pacific Time, due to study feasibility.
SWOG S1400G
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
NCT#03377556
(Click for More Info)
S1400G is permanently closed to accrual effective July 23, 2018.
SWOG S1400I
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)
Eligible for screening study DCP 001
(See required screening study SWOG S1400)
NCT#02785952
(Click for More Info)
S1400I is permanently closed to accrual effective immediately, April 23, 2018. At a planned interim analysis, SWOG’s Data and Safety Monitoring Committee recommended that sub study S1400I be permanently closed to accrual based on the results. This information will be shared and further instructions given in a forthcoming letter to patients and investigators. Patients currently receiving the experimental combination nivolumab plus ipilimumab may continue to receive treatment if the patient is deriving clinical benefit, the patient agrees to continue treatment, and if their physician feels that it is in the best interest of the patient to continue the treatment as an appropriate medical intervention at this time. Patients on both arms should continue study follow-up.
SWOG S1400K
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of ABBV-399 (Process II) in Patients with
c-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer
(Lung-MAP Sub-Study)
S1400K will be temporarily closed to accrual 10/18/18 based on additional review of the safety data.
At a planned interim analysis, the study team reviewed patient data to date and did not find that every 3-week dosing of ABBV-399 was sufficiently active to continue enrolling patient to the study. S1400K will be permanently closed, on 12/21/18, to accrual based on the results.
(See required screening study SWOG S1400)
NCT#03574753
(Click for More Info)
SWOG S1403
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)
NCT#02438722
(Click for More Info)
S1403 is permanently closed to accrual effective immediately, 04/23/18.
SWOG S1507
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
NCT#02642042
(Click for More Info)
S1507 has met its accrual goal and will permanently close to accrual effective March 15, 2018 at 11:59 p.m. Pacific.
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
SWOG S1800A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
NCT#03971474
(Click for More Info)
S1800A is permanently closed to accrual effective November 16, 2020.
SWOG S1827
Primary Category:
Radiation Oncology
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Eligible for screening study DCP 001
NCT#04155034
(Click for More Info)
SWOG S1900A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
NCT#03845296
(Click for More Info)
See Screening Protocol LUNGMAP
Cohort 1 (patients with squamous cell lung cancer) permanently closed to accrual effective November 15, 2020.
Cohort 2 (patients with non-squamous cell lung cancer) is temporarily closed effective April 6, 2020.
SWOG S1900B
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
NCT#04268550
(Click for More Info)
See Screening Protocol LUNGMAP
SWOG S1900C
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
New, Temporarily Closed
A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
NCT#04173507
(Click for More Info)
S1900C is temporarily closed to accrual effective November 16, 2020.
SWOG S1914
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Eligible for screening study DCP 001
(Click for More Info)
NCT#04214262
SWOG S1929
Primary Category:
Treatment Protocols
Disease Category:
Lung - Small Cell Extensive Stage
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
(Click for More Info)
NCT#04334941
SWOG S1933
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung - Non-Small Cell
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
(Click for More Info)
NCT#04310020
Lymphoma
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A021602
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A051301
Primary Category:
Treatment Protocols
Disease Category:
Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Coverage Analysis WorksheetA Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
Eligible for screening study DCP 001
NCT#02443077
(Click for More Info)
This study is open to FACT-accredited institutions only.
Site Delegation of Tasks Log required prior to registration of any patients.
ALLIANCE A051701
Primary Category:
Treatment Protocols
Disease Category:
Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
NCT#03984448
(Click for More Info)
Effective 09/28/20, accrual of patients of all ages with double hit lymphoma (DHL) is temporarily halted.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ECOG-ACRIN E4412
Primary Category:
Treatment Protocols
Disease Category:
Hodgkin Lymphoma, Lymphoma
A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
NCT#01896999
(Click for More Info)
Open to Phase II accrual.
ECOG-ACRIN EA4151
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
NCT#03267433
(Click for More Info)
Eligible for screening study DCP 001
ECOG-ACRIN EA4181
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
(Click for More Info)
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
SWOG S1608
Primary Category:
Treatment Protocols
Disease Category:
Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
NCT#03269669
(Click for More Info)
SWOG S1826
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Hodgkin Lymphoma, Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
NCT#03907488
Eligible for screening study DCP 001
(Click for More Info)
Molecular Profiling
ALLIANCE A071701
Primary Category:
Treatment Protocols
Disease Category:
Brain, Brain Metastatic, Molecular Profiling
Genomically-Guided Treatment Trial in Brain Metastases
(Click for More Info)
ALLIANCE A081105
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
A081105 is reactivated effective July 15, 2020.
NCT#02193282
(Click for More Info)
ALLIANCE A151216
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105, E4512, and EA5142.
Eligible for screening study DCP 001
Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.
NCT#02194738
(Click for More Info)
ECOG-ACRIN E4512
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02201992
(Click for More Info)
ECOG-ACRIN EA5142
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02595944
(Click for More Info)
Effective today, October 1st, 2019, study EA5142 has met accrual goals and is permanently closed to accrual.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
ECOG-ACRIN EAY131-A
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-C1
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
(See required screening study ECOG-ACRIN EAY131)
EAY131 C1 substudy, is reactivated, May 7, 2020, to allow for expanded accrual.
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-C2
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-E
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
(See required screening study ECOG-ACRIN EAY131)
EAY131-E is reopened effective, October 10, 2020.
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-H
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)
(See required screening study ECOG-ACRIN EAY131)
EAY131-H has expanded its accrual goal, therefore it is reactivated effective 10/02/2020.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-J
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
(See required screening study ECOG-ACRIN EAY131)
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
Effective June 14, 2019, sub-study EAY131-J is temporarily closed to accrual.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-K2
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
Effective today, July 18th, 2019, Subprotocol K2: Phase 2 is suspended due to the completion of accrual.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-L
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-M
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
(See required screening study ECOG-ACRIN EAY131)
EAY131 Subprotocol M, is reactivated, May 7, 2020, with expanded accrual.
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-V
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-Z1C
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
(See required screening study ECOG-ACRIN EAY131)
EAY131 (MATCH) Subprotocol Z1C, is reactivated, May 7, 2020, to allow for expanded accrual.
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-Z1E
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-Z1G
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1G: Phase 2 STudy of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-Z1K
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling, Other
Molecular Analysis for Therapy Choice – Phase 2 Study of the Selective ATP-Competitive Inhibitor Ipatasertib (GDC-0068) in Patients with Tumors with AKT Mutation
(See required screening study ECOG-ACRIN EAY131)
Subprotocol EAY131-Z1K has reached its accrual goal and is, therefor permanently closed to accrual effective 11/13/20
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
NCI 9671
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Molecular Profiling, Other
Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are exceptional responders
All cases must be provisionally approved by NCI, before enrollment. Once a case is approved by NCI, then the IRB approval process takes place.
NCI 9761 is closed to accrual effective November 21, 2017.
NCT#02243592
(Click for More Info)
SWOG S1400
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Eligible for screening study DCP 001
NCT#02154490
(Click for More Info)
Closure to accrual for S1400 is effective January 28, 2019.
SWOG S1400A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Permanent Closure of S1400A, Arm 2-Docetaxel due to FDA approval of nivolumab. Permanent closure of sub-study due to a revised trial design.
NCT#02154490
(Click for More Info)
SWOG S1400B
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
S1400B is closed to accrual effective December 12, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400C
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Permanent closure of Arm 2 ONLY due to a revised trial design.
S1400C will be permanently closed to accrual, effective September 1, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400D
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Effective 11:59 p.m. Pacific Time on October 31, 2016, the following sub-study will be permanently closed to accrual, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400E
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-MET Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
(See required screening study SWOG S1400)
NCT#02154490
(Click for More Info)
SWOG S1400F
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTIPD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)
See Screening Protocol LUNGMAP
NCT#03373760
(Click for More Info)
Effective November 6th, 2019 at 2:00 pm Pacific Time, Cohort 1, the acquired resistance cohort of substudy S1400F will permanently close to accrual. Please note that Cohort 2, the primary resistance cohort, has been reactivated and is open to accrual.
S1400F Cohort 2, the primary resistance cohort, will be permanently closed to accrual effective March 24, 2020 at 12:00 p.m. Pacific Time, due to study feasibility.
SWOG S1400G
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
NCT#03377556
(Click for More Info)
S1400G is permanently closed to accrual effective July 23, 2018.
SWOG S1400I
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)
Eligible for screening study DCP 001
(See required screening study SWOG S1400)
NCT#02785952
(Click for More Info)
S1400I is permanently closed to accrual effective immediately, April 23, 2018. At a planned interim analysis, SWOG’s Data and Safety Monitoring Committee recommended that sub study S1400I be permanently closed to accrual based on the results. This information will be shared and further instructions given in a forthcoming letter to patients and investigators. Patients currently receiving the experimental combination nivolumab plus ipilimumab may continue to receive treatment if the patient is deriving clinical benefit, the patient agrees to continue treatment, and if their physician feels that it is in the best interest of the patient to continue the treatment as an appropriate medical intervention at this time. Patients on both arms should continue study follow-up.
SWOG S1400K
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of ABBV-399 (Process II) in Patients with
c-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer
(Lung-MAP Sub-Study)
S1400K will be temporarily closed to accrual 10/18/18 based on additional review of the safety data.
At a planned interim analysis, the study team reviewed patient data to date and did not find that every 3-week dosing of ABBV-399 was sufficiently active to continue enrolling patient to the study. S1400K will be permanently closed, on 12/21/18, to accrual based on the results.
(See required screening study SWOG S1400)
NCT#03574753
(Click for More Info)
SWOG S1609
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NCT#02834013
(Click for More Info)
Eligible for screening study DCP 001
Please see http://www.swogstat.org/accrual/dart.htm for up-to-date accrual information and current cohort accrual status (i.e. open, closed, suspended). The website is updated with the most current information daily.
Multiple Myeloma
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A011203
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
NCT#02311933
(Click for More Info)
A011203 is permanently closed to accrual effective May 19, 2017.
ALLIANCE A061402
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Multiple Myeloma, Other
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
Eligible for screening study DCP 001
NCT#02516423
(Click for More Info)
Alliance A061402 is permanently closed to new patient registration (Step 1) effective August 15, 2019, .
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A171601
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
NCT#03633331
(Click for More Info)
Eligible for screening study DCP 001
Effective Tuesday, March 3rd, 2020, at 4:30 PM ET, study A171601 is permanently closed to new patient registration.
ALLIANCE A231602CD
Primary Category:
Cancer Care Delivery
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia, Multiple Myeloma
Status:
Open, Temporarily Closed
Assessing Financial Difficulty in Patients with Blood Cancers
NCT#03870633
(Click for More Info)
Eligible for screening study DCP 001
A231602CD has reached accrual goal. Therefore, effective June 9, 2020, it is temporarily closed to accrual. Update to increase is under consideration with trial closed until determination is made.
Limited site participation. Open only to Benefis Sletten Cancer Institute, Billings Clinic, Community Hospital of Anaconda, Community Medical Center, and Saint Alphonsus Regional Medical Center
ECOG-ACRIN E1A11
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Eligible for screening study DCP 001
NCT#01863550
(Click for More Info)
E1A11 is closed to accrual, January 29, 2019 at 5:00pm ET.
ECOG-ACRIN E2108
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic, Breast Neoadjuvant
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
E2108 is closed to accrual effective July 23, 2015 at 5:00 p.m. EDT.
NCT#01242800
(Click for More Info)
ECOG-ACRIN E3A06
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
NCT#01169337
(Click for More Info)
E3A06 is successfully approaching its accrual goal. A pending closure date has been set for July 14, 2017 at 5:00pm ET for new patient registration.
ECOG-ACRIN EA1183
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
(Click for More Info)
NCT#04316117
ECOG-ACRIN EAA173
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Eligible for screening study DCP 001
(Click for More Info)
NCT#03937635
NRG BR002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
Temporarily Closed
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Effective, Friday, September 13th, 2019, study NRG BR002 is temporarily closed to accrual at 3 p.m. MST.
NCT#02364557
(Click for More Info)
NRG BR004
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
NCT#03199885
(Click for More Info)
SWOG S1416
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
NCT#02595905
(Click for More Info)
Effective, today, June 15th, 2019, SWOG S1416, is permanently closed to accrual.
SWOG S1501
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Eligible for screening study DCP 001
NCT#03418961
(Click for More Info)
SWOG S1703
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NCT#03723928
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1803
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Eligible for screening study DCP 001
Occupational Report & Pregnancy Report consent forms available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consents and for any questions.
(Click for More Info)
Neuroendocrine
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A021602
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A221701
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Gastrointestinal, Genitourinary, Neuroendocrine, Pancreatic, Renal
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention versus Early Treatment Approaches
NCT#03839940
(Click for More Info)
Eligible for screening study DCP 001
A221701 is closed to new patient accrual, effective November 1, 2020.
ECOG-ACRIN EA2142
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Neuroendocrine
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
(Click for More Info)
NCT#02595424
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
Other
ALLIANCE A011106
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Eligible for screening study DCP 001
NCT#01953588
(Click for More Info)
Effective today, July 15th, 2019, study A011106 is permanently closed to new patient registration.
ALLIANCE A011401
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Eligible for screening study DCP 001
NCT#02750826
(Click for More Info)
The A011401 Health Behaviors and Patient Reported Outcomes substudy HO1 will soon meet its study accrual goal. Therefore, EFFECTIVE July 06, 2017 at 4:30 pm ET, A011401 substudy HO1 will permanently close to new patient accrual.
ALLIANCE A061402
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Multiple Myeloma, Other
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
Eligible for screening study DCP 001
NCT#02516423
(Click for More Info)
Alliance A061402 is permanently closed to new patient registration (Step 1) effective August 15, 2019, .
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A221602
Primary Category:
Cancer Control and Prevention Protocols
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
NCT#03578081
(Click for More Info)
Eligible for screening study DCP 001
DCP 001
Primary Category:
Cancer Control and Prevention Protocols
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
ECOG-ACRIN E2108
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic, Breast Neoadjuvant
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
E2108 is closed to accrual effective July 23, 2015 at 5:00 p.m. EDT.
NCT#01242800
(Click for More Info)
ECOG-ACRIN EA1181
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
(Click for More Info)
NCT#04266249
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
ECOG-ACRIN EAY131-Z1K
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling, Other
Molecular Analysis for Therapy Choice – Phase 2 Study of the Selective ATP-Competitive Inhibitor Ipatasertib (GDC-0068) in Patients with Tumors with AKT Mutation
(See required screening study ECOG-ACRIN EAY131)
Subprotocol EAY131-Z1K has reached its accrual goal and is, therefor permanently closed to accrual effective 11/13/20
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
NCI 9671
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Molecular Profiling, Other
Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are exceptional responders
All cases must be provisionally approved by NCI, before enrollment. Once a case is approved by NCI, then the IRB approval process takes place.
NCI 9761 is closed to accrual effective November 21, 2017.
NCT#02243592
(Click for More Info)
NCI COVID-19
Primary Category:
Treatment Protocols
Status:
Temporarily Closed
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Eligible for screening study DCP 001
Effective August 6, 2020, temporarily closed to accrual locally pending administrative review
(Click for More Info)
NCT#04387656
NRG B-51
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#01872975
(Click for More Info)
NSABP B-51 is projected to meet accrual goal during the 1st Quarter of 2021. Closure date pending.
The accrual goal for the Behaviorial and Health Outcomes (BAHO) Quality of Life component in the B-51 trial has been met. Therefore, effective August 6th, 2018, accrual will be closed to the QoL component. The B-51 trial remains open to accrual.
NRG B-52
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
B-52 is closed to accrual effective February 29, 2016, 8 pm EST.
NCT#02003209
(Click for More Info)
NRG B-55
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#02032823
(Click for More Info)
B-55 is closed to accrual effective April 29, 2019.
Closure of Part 1 and Part 2 Screening will occur on April 1, 2019 at 5:00 PM Eastern Time. Accrual to the NSABP B-55/BIG 6-13 trial will close on April 29, 2019 at 5:00 PM Eastern Time. Patients, who are in screening, must be randomized to the study by 5:00 PM on April 29, 2019.
Protocol
NRG BR005
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Status:
Temporarily Closed
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery
NCT#03188393
Effective today, July 2, 2019, study NRG BR005 is temporarily closed to accrual.
(Click for More Info)
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
SWOG S1701
Primary Category:
Treatment Protocols
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
NCT#03694002
(Click for More Info)
SWOG S1702
Primary Category:
Treatment Protocols
A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
NCT#03499808
(Click for More Info)
Sarcoma
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A091401
Primary Category:
Treatment Protocols
Disease Category:
Sarcoma
Randomized Phase II Study of Nivolumab with or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma
NCT#02500797
(Click for More Info)
Effective Thursday, August 1, 2019, Alliance A091401 is permanently closed to new patient accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG DT001
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Sarcoma
Status:
Temporarily Closed
A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
NCT#03217266
(Click for More Info)
Effective 09/15/20, NRG DT001, Cohort A (extremity/body wall), is reopened at Dose level 3.
Effective, 04/24/20, NRG DT001, Cohort B, is reactivated to Dose Level 2.
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
Skin
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
NCT#02744092
(Click for More Info)
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Permanent Closure, effective 04/23/20. Accrual goal met.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A091802
Primary Category:
Treatment Protocols
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
NCT#03944941
(Click for More Info)
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ECOG-ACRIN EA6134
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Eligible for screening study DCP 001
NCT#02224781
(Click for More Info)
ECOG-ACRIN EA6141
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
NCT#02339571
(Click for More Info)
This protocol has additional training requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
ECOG-ACRIN EA6174
Primary Category:
Treatment Protocols
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
NCT#03712605
(Click for More Info)
Eligible for screening study DCP 001
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
(Sub-study for EAY131)
Eligible for screening study DCP 001
NCT#02823652
(Click for More Info)
MCC not eligible to participate in new addendum, as EAQ152 is only open to accrual at select sites.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Status:
Open, Temporarily Closed
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
SWOG S1404
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Skin
A Phase III Randomized Trial Comparing Physician/Patient Choice of High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Eligible for screening study DCP 001
NCT#02506153
(Click for More Info)
Step 1 (prestudy screening) of S1404 study has reached its accrual goal and will be permanently closed to accrual effective August 15, 2017 at 11:59 p.m. Pacific Time.
Step 2 (randomization) of S1404 will be permanently closed to accrual effective November 2, 2017 at 11:59 p.m. Pacific Time.
SWOG S1512
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Skin
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
NCT#02775851
(Click for More Info)
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
SWOG S1616
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti PD-L1 Agent
NCT#03033576
(Click for More Info)
S1616 is permanently closed to accrual effective July 15, 2020.
SWOG S1801
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
NCT#03698019
(Click for More Info)
Solid tumor or Hematologic Malignancy
ECOG-ACRIN EAQ172
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Solid tumor or Hematologic Malignancy
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Eligible for screening study DCP 001
(Click for More Info)
NCT#04438382
Thyroid
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
SWOG S1614
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Status:
Temporarily Closed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
NCT#03887702
(Click for More Info)
S1614 is temporally closed to accrual effective May 20, 2020.
